Urata Y - In RA patients, the development of malignant tumors that could be designated for immune checkpoint (IC) was examined every year from September 2014 in order to elucidate the incidence of malignancies to which IC inhibitors (ICI) are designated in RA, a typical autoimmune disease. Because of a rise in malignant tumor incidence, development of a new IC (methods), the combined use of IC and other cancer treatment methods, and expansion of IC indication diseases, the incidence of IC-adapted malignancy had progressed in RA. Awareness of malignant tumor treatment is required for rheumatologists, because of the coexistence of autoimmune diseases and malignancy therapy.